Related Experiment Video
Updated: Sep 13, 2026
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
Innovative strategies in lymphoma therapy
1Division of Hematology and Hemostaseology, Department of Internal Medicine I, University of Vienna, Vienna, Austria. ulrich.jaeger@akh-wien.ac.at
Abstract:
Treatment of malignant non-Hodgkin lymphomas (NHL) in the 21st century has been revolutionized by novel biological agents offering targeted approaches in addition to radio-chemotherapy. Monoclonal antibodies (MoAbs) against lymphatic surface antigens have been effective as monotherapeutic agents, and have already shown their superiority to conventional strategies when combined with chemotherapy. Radioimmunoconjugates are more effective than unlabelled antibodies. Specific inhibitors of neoangiogenesis as well as intracellular signal transduction pathways and antiapoptotic mechanisms have shown their efficacy in phase II studies. Long-term improvement in the setting of minimal residual disease has been observed after vaccination against surface antigens and non-myeloablative allogeneic stem cell transplantation is effective in controlling lymphoma growth. Novel specific antigens are currently identified using expression profiling of lymphomas. In the near future, combinations of biological agents will challenge conventional therapy. These exciting new strategies will improve the success rate in aggressive NHLs and may even challenge the paradigm of incurability of indolent lymphomas.
Insights
Novel biological agents are revolutionizing non-Hodgkin lymphoma (NHL) treatment. These targeted therapies, including monoclonal antibodies and new inhibitors, show promise in improving outcomes for aggressive and indolent lymphomas.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Malignant non-Hodgkin lymphomas (NHL) treatment has evolved significantly.
- Traditional radio-chemotherapy faces limitations in efficacy and toxicity.
Purpose of the Study:
- To review advancements in 21st-century NHL treatment strategies.
- To highlight the impact of novel biological agents and targeted therapies.
Main Methods:
- Review of current literature on biological agents in NHL treatment.
- Analysis of data from phase II studies on novel therapies.
- Discussion of emerging strategies including monoclonal antibodies, radioimmunoconjugates, signal transduction inhibitors, and immunotherapy.
Main Results:
- Monoclonal antibodies (MoAbs) demonstrate efficacy alone and superior outcomes when combined with chemotherapy.
- Radioimmunoconjugates are more effective than unlabelled antibodies.
- Inhibitors of neoangiogenesis, signal transduction, and antiapoptotic mechanisms show promise.
- Vaccination and allogeneic stem cell transplantation offer long-term disease control.
Conclusions:
- Novel biological agents are revolutionizing NHL treatment, offering targeted approaches.
- Future strategies involving combinations of biological agents will improve success rates in aggressive NHL.
- These advancements may challenge the incurability paradigm for indolent lymphomas.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...